中国药物经济学2025，Vol.20Issue(7)：19-26,31,9.DOI:10.12010/j.issn.1673-5846.2025.07.003
罗普司亭二线治疗原发免疫性血小板减少症的药物经济学评价
Pharmacoeconomic Evaluation of Roprestine as Second-line Treatment for Primary Immune Thrombocytopenia
程文迪 1罗雅双 1符雨嫣 1王海银1
作者信息
- 1. 上海市卫生和健康发展研究中心(上海市医学科学技术情报研究所),上海 201199
- 折叠
摘要
Abstract
Objective This study aimed to estimate the cost-effectiveness of Romiplostim(ROMI)compared to Herombopag/Hetrombopag(HPAG)as a second-line treatment for Chinese adult chronic primary immune thrombocytopenia(ITP).Methods From the perspective of China's health system,a three-state Markov model embedded in a decision tree was constructed.Based on the evidence of matching adjustment and indirect comparison,the economic efficiency of roprestine versus haltrombopag as second-line treatment for adult ITP patients in China was evaluated.The model cycle is 6 weeks for the decision tree stage,the model cycle is 4 weeks for the Markov stage,and the simulation time limit is the entire life cycle,The main output results of the model are total cost,quality-adjusted life years(QALYs),and incremental cost-effectiveness ratio(ICER),with a discount rate of 5%for cost and effectiveness.Taking one times China's per capita GDP in 2022(85,698 yuan)as the threshold of willingness to pay,the cost-effectiveness analysis method was adopted for analysis,and the robustness of the model was verified by using scenario analysis,single-factor sensitivity analysis,and probabilistic sensitivity analysis.Results The basic analysis results show that compared with the heltrombopag group,the incremental effect of the roprestine group is 0.014 QALYs,and the per capita cost is reduced by 3 661 yuan.Therefore,the basic analysis results consider roprestine to be a scheme with absolute economic advantages The results of the situational analysis are consistent with those of the basic analysis.The results of univariate sensitivity analysis indicated that the long-term platelet response rate of Ropustine and the hypothetical price of Ropustine had a significant impact on the incremental net monetary gain(INMB)results.The results of the probabilistic sensitivity analysis show that when the threshold is 1 times and 3 times China's per capita GDP in 2022,respectively,the probability that Ropstine is economically viable is 89.20%and 94.60%.Conclusion ROMI is cost effectiveness in second-line treatment for Chinese adult patients with ITP.关键词
罗普司亭/原发免疫性血小板减少症/匹配调整间接比较/成本-效果分析/Markov模型Key words
Romiplostim/Primary immune thrombocytopenia/Matching-adjusted indirect comparison/Cost-effectiveness analysis/Markov model分类
医药卫生引用本文复制引用
程文迪,罗雅双,符雨嫣,王海银..罗普司亭二线治疗原发免疫性血小板减少症的药物经济学评价[J].中国药物经济学,2025,20(7):19-26,31,9.
